- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07897357
Trained vs. Untrained: Lower Extremity Pressure Changes (TULiP)
Central Blood Volume Shifts in Healthy Adults With Varying Levels of Fitness: Effects on Lung Diffusing Capacity
Research shows that how well oxygen moves from the lungs into the blood (called lung diffusing capacity) is linked to a person's aerobic fitness and endurance training. People who exercise regularly often have different lung and heart responses than people who do not. The exact reasons for these differences are still unclear. This study will test one possible explanation: highly trained people may handle changes in the amount of blood returning to the heart differently than people who are not trained. We want to learn how the blood vessels in the lungs react when the amount of blood entering the heart changes, and how this reaction is affected by fitness level. To do this, we will change how much blood returns to the heart by applying air pressure around the legs, similar to a light vacuum. These changes are expected to be similar to what happens when someone moves from lying down to standing up.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Purpose and hypothesis
The purpose of the current study is to determine the impact of endurance training status and biological sex on pulmonary diffusing capacity for carbon monoxide (DLCO) and its components (pulmonary capillary blood volume [Vc] and pulmonary membrane diffusing capacity [Dm]) during acute changes in central blood volume using varying levels of lower body positive and negative pressure (LBPP and LBNP) and head down and head up tilt (HDT and HUT).
The investigators hypothesize that for a given reduction (i.e., LBNP, HUT) or increase (i.e., LBPP, HDT) in central blood volume, endurance-trained individuals will demonstrate greater changes in DLCO compared to untrained individuals. As a second exploratory aim, the investigators hypothesize that females will have larger changes in DLCO compared to males.
Research Method/Procedures
All visits will happen on separate days with at least 24 hours between visits. All visits will take place within 4 months.
Visit 1: Screening
On the screening day, the participant will complete the informed consent procedure, fill out a medical history form, and be screened for exercise using the modified medical research council (mMRC) dyspnea scale, PAR-Q+ exercise readiness questionnaire and the Physical Activity and Sedentary Behaviour Questionnaire (PASB-Q). The investigators will then perform pulmonary function tests on each participant. Finally, the participant will complete a graded exercise test on an upright cycle ergometer to volitional exhaustion to determine maximal oxygen consumption (V̇O2max). Evaluation of dyspnea including intensity and unpleasantness will be performed at each workload. Further, reasons for test termination, dyspnea, and qualitative descriptors of dyspnea will be evaluated at peak exercise. Hemoglobin concentration will be measured via finger prick prior to and following completion of exercise testing.
Visit 2: Central Blood Volume Manipulation and DLCO
The participant will perform the DLCO test at various levels of LBNP/LBPP ranging from -80 mmHg to +40 mmHg, or HUT/HDT ranging between 90° and -12°. Head tilt and lower body pressure changes provide a similar intervention that can be used interchangeably based on equipment availability. Changes in central blood volume during LBNP/HUT are equivalent to standing upright (-80 mmHg LBNP or 90° HUT), and changes in central blood volume during LBPP/HDT are equivalent to someone lying down with their feet above their head (+40 mmHg LBPP or -12° HDT). For the LBNP/LBPP trials, participants will lay supine with their lower body (from the iliac crest to their toes) inside the pressure chamber. The participant's lower body will be sealed within the differential pressure chamber using a neoprene skirt to prevent any air leakage from the insides of the chamber. Negative and positive pressures are induced by a vacuum pump that either reduces or increases pressure inside the chamber in a controlled and precise manner. The vacuum pump is controlled by a trained member of the research team, and chamber pressure is continuously monitored via a digital manometer. For the HUT/HDT trials, the participant will lie supine on a tilt table. The table will be electronically adjusted to the desired angle at a rate of 1°/second.
Once participants are secured in the lower body pressure chamber or on the tilt table, a certified technician will insert an intravenous (IV) catheter into an antecubital vein which will allow peripheral venous pressure measurements. Participants will also be equipped with a continuous blood pressure monitor, a brachial blood pressure cuff, an electrocardiogram, and a thoracic impedance device. Each stage of LBPP/LBNP or HUT/HDT will begin with two minutes of stabilization followed by two DLCO breath-hold maneuvers. At each stage participants will also breathe on a mouthpiece for two minutes to collect metabolic data: ventilation (V̇E), oxygen consumption (V̇O2), and carbon dioxide production (V̇CO2). Cardiovascular parameters (blood pressure, peripheral venous pressure, heart rate, thoracic impedance) will be measured continuously. Hemoglobin will be measured at each stage via a small (< 1 mL) blood sample from the IV. At the end of the trial, a certified technician will obtain a ~5 mL blood sample from the IV for sex hormone analyses.
Participants will not complete more than 15 DLCO breath holds during each experimental visit. As per recommendations, participants will perform standard DLCO breath-hold maneuvers for 6 seconds, and maneuvers will be performed twice at each stage. A washout period of at least 4 minutes between each breath hold will be completed to ensure adequate recovery and blood gas equilibration.
Visit 3: DLCO with Exercise
Exercise will be used as a physiological stressor to increase central blood volume beyond that of LBPP or HDT. The participant will perform the DLCO maneuvers during exercise at varying exercise intensities (~20%-100% of an individual's V̇O2max). Participants will not complete more than 15 breath holds during the experimental visit. As per recommendations, participants will perform standard DLCO breath-hold maneuvers for 6 seconds, and maneuvers will be performed twice at each stage. At each exercise intensity, participants will breathe on a mouthpiece for two minutes to collect metabolic data; heart rate and peripheral oxygen saturation will be measured continuously for the same two minutes at each intensity. Blood pressure will be measured once per stage with an automatic sphygmomanometer. Hemoglobin via finger prick will also be measured at each intensity. A washout period of at least 2 minutes between each breath hold during exercise will be completed to ensure adequate recovery and blood gas equilibration. At the end of the trial, a certified technician will obtain a ~5 mL blood sample from an antecubital vein for sex hormone analyses.
Visit 4: Ultrasound with LBNP/HUT, LBPP/ HDT, and Exercise
Participants will complete the same interventions as visit 2 (LBNP/LBPP -80 to +40 mmHg, or HUT/HDT 90° to -12°) and visit 3 (exercise at ~20%-100% of an individual's V̇O2max). At each stage of LBNP/LBPP or HUT/HDT, and exercise, a trained sonographer will obtain images of the heart via echocardiography. Participants will then undergo a carbon monoxide rebreathe protocol to estimate blood volume. A certified technician will insert an IV catheter into an antecubital vein to collect serial blood samples. While lying supine, participants will inhale a bolus of carbon monoxide (0.7-1.0 mL/kg bodyweight) mixed with 100% oxygen on a rebreathing circuit for two minutes and will then continue to rest for eight additional minutes. Venous blood samples measuring carboxyhemoglobin before the rebreathe and eight minutes after the rebreathe will allow the calculation of blood volume.
Visit 5: Computed Tomography
Participants will report to a Medical Imaging Centre for the computed tomography (CT) scan. Following a briefing by the Medical Imaging Centre staff, participants will lay supine on the CT scanner and the region of interest in the chest will be obtained. The participant will remain as still as possible and inhale to total lung capacity and hold their breath. During the breath hold, images will be acquired. The participant will then empty their lungs as far as they can and imaging will be repeated.
CT can noninvasively detect features of pulmonary vascular dysfunction. CT outcomes-such as pulmonary artery diameter, vessel pruning, perfusion heterogeneity, and right ventricular morphology-correlate with hemodynamic abnormalities and impaired pulmonary vascular reserve. These imaging biomarkers enable early identification and monitoring of pulmonary vascular disease, providing clinically relevant information beyond conventional structural assessment. In healthy individuals, CT can provide valuable information characterizing pulmonary structure not available using other non-invasive techniques. For example, CT can provide quantitative information on pulmonary vascular and airway branching to show potential structural differences inherent to highly fit individuals. CT is therefore a tool to characterize differences in lung structure which may also potentially explain differences in lung function elucidated by the other measures in this study.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Desi P Fuhr, MSc
- Phone Number: 780-492-1121
- Email: fuhr@ualberta.ca
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2R3
- Recruiting
- Clinical Physiology Laboratory
-
Contact:
- Michael K Stickland, PhD
- Phone Number: 780-492-3995
- Email: michael.stickland@ualberta.ca
-
Contact:
- Desi P Fuhr, MSc
- Phone Number: 780-492-1121
- Email: fuhr@ualberta.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-40 years old.
Exclusion Criteria:
- Severe obesity (body mass index >35 kg/m2).
- Self-reported blood donation or transfusion in the past 60 days. Large artificial fluctuations in blood volume may impact the findings of the present study.
- Pregnancy. To confirm this, women not using contraception will be given a pregnancy test. Pregnancy presents additional complications and may confound the results of the study; therefore, pregnant women will be excluded.
- Known chronic disease (heart failure, hypertension, diabetes, asthma, chronic obstructive pulmonary disease, renal disease).
- Participants with known postural orthostatic tachycardic syndrome or orthostatic hypotension.
- Participants who currently smoke cigarettes (within the last month) or those who have >1 pack-year smoking history.
- Participants who currently smoke cannabis products (within the last month) or those who have >1 joint-year cannabis history.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: All participants
All participants complete all five visits as outlined in the study description. |
Graded lower body positive pressure (+10, +20, +30 mmHg) and negative pressure (-15, -30, -45, -60 mmHg). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in diffusing capacity for carbon monoxide (DLCO)
Time Frame: Days 2 and 3. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.
|
Diffusing capacity of carbon monoxide (DLCO) in selected exercise intensities, lower-body pressures, and body positions. DLCO is measured using the single-breath dual gas pulmonary diffusing capacity for nitric oxide and carbon monoxide technique. |
Days 2 and 3. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.
|
|
Change in capillary blood volume (Vc)
Time Frame: Days 2 and 3. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.
|
Capillary blood volume is a component of DLCO and is measured with the single-breath dual gas pulmonary diffusing capacity for nitric oxide and carbon monoxide technique. |
Days 2 and 3. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.
|
|
Change in membrane diffusing capacity (Dm)
Time Frame: Days 2 and 3. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.
|
Membrane diffusing capacity is a component of DLCO and is measured with the single-breath dual gas pulmonary diffusing capacity for nitric oxide and carbon monoxide technique. |
Days 2 and 3. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cardiac structure and function
Time Frame: Day 4. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.
|
Echocardiography-derived right ventricular systolic pressure during exercise and lower-body pressure conditions. |
Day 4. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.
|
|
Change in peripheral venous pressure
Time Frame: Day 2. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.
|
Measured directly using the antecubital IV during lower body positive and negative pressure. |
Day 2. Measurements will be taken during each stage of intervention (e.g., LBPP/LBNP), after a minimum of 2 minutes from the onset of each stage.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael K Stickland, PhD, University of Alberta
Publications and helpful links
General Publications
- Tedjasaputra V, Bouwsema MM, Stickland MK. Effect of aerobic fitness on capillary blood volume and diffusing membrane capacity responses to exercise. J Physiol. 2016 Aug 1;594(15):4359-70. doi: 10.1113/JP272037. Epub 2016 May 12.
- Brotto AR, de Waal S, D'Souza AW, Beaudry RI, Ehnes CM, Collins SE, Fuhr DP, van Diepen S, Stickland MK. Impact of body posture on pulmonary diffusing capacity at rest and during exercise in endurance-trained and untrained individuals. J Appl Physiol (1985). 2025 Jan 1;138(1):301-310. doi: 10.1152/japplphysiol.00447.2024. Epub 2024 Dec 16.
- Shi X, Crandall CG, Raven PB. Hemodynamic responses to graded lower body positive pressure. Am J Physiol. 1993 Jul;265(1 Pt 2):H69-73. doi: 10.1152/ajpheart.1993.265.1.H69.
- Lalande S, Yerly P, Faoro V, Naeije R. Pulmonary vascular distensibility predicts aerobic capacity in healthy individuals. J Physiol. 2012 Sep 1;590(17):4279-88. doi: 10.1113/jphysiol.2012.234310. Epub 2012 Jun 25.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Pro00160257
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.